ATE309352T1 - Inhibitoren der nf-kb aktivierung - Google Patents

Inhibitoren der nf-kb aktivierung

Info

Publication number
ATE309352T1
ATE309352T1 AT99924594T AT99924594T ATE309352T1 AT E309352 T1 ATE309352 T1 AT E309352T1 AT 99924594 T AT99924594 T AT 99924594T AT 99924594 T AT99924594 T AT 99924594T AT E309352 T1 ATE309352 T1 AT E309352T1
Authority
AT
Austria
Prior art keywords
inhibitors
kappab
activation
ikappab
traf
Prior art date
Application number
AT99924594T
Other languages
English (en)
Inventor
Rudi Beyaert
Karen Heyninck
Walter Fiers
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE309352T1 publication Critical patent/ATE309352T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT99924594T 1998-05-06 1999-05-05 Inhibitoren der nf-kb aktivierung ATE309352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98201472 1998-05-06
PCT/BE1999/000055 WO1999057133A2 (en) 1998-05-06 1999-05-05 Inhibitors of nf-kb activation

Publications (1)

Publication Number Publication Date
ATE309352T1 true ATE309352T1 (de) 2005-11-15

Family

ID=8233686

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99924594T ATE309352T1 (de) 1998-05-06 1999-05-05 Inhibitoren der nf-kb aktivierung

Country Status (9)

Country Link
US (2) US6673897B1 (de)
EP (1) EP1075519B1 (de)
JP (1) JP2002513552A (de)
AT (1) ATE309352T1 (de)
AU (1) AU754434B2 (de)
CA (1) CA2328483A1 (de)
DE (1) DE69928244T2 (de)
ES (1) ES2251831T3 (de)
WO (1) WO1999057133A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309352T1 (de) 1998-05-06 2005-11-15 Vlaams Interuniv Inst Biotech Inhibitoren der nf-kb aktivierung
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
JP4252446B2 (ja) * 2001-06-22 2009-04-08 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） Ａｂｉｎにより媒介される肝炎防護
US7700553B2 (en) 2003-09-24 2010-04-20 Institut Pasteur Selective inhibition of NF-κB activation by peptides designed to disrupt nemo oligomerization
WO2006029981A1 (en) * 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
CN1304418C (zh) * 2005-02-22 2007-03-14 中国人民解放军第三军医大学第三附属医院 核因子－κB p65亚基拮抗肽及其应用
EP1871406A1 (de) 2005-04-14 2008-01-02 VIB vzw Behandlung von egfr-abhängigen tumoren durch abin (a20-bindungs-hemmer von nf-kappab)
ES2729501T3 (es) * 2006-10-30 2019-11-04 Centre Nat Rech Scient Ensayo de gen indicador, kit y células con sensibilidad y/o especificidad mejoradas para determinar el nivel del TNF-gamma
CN101307094B (zh) * 2008-03-21 2011-09-28 中国人民解放军第三军医大学第三附属医院 一种核因子-κB p65亚基拮抗多肽
CN101798336B (zh) * 2009-02-06 2012-02-29 中国人民解放军第三军医大学第三附属医院 一种具有示踪功能的抗肿瘤化合物
CN111606976A (zh) * 2020-05-26 2020-09-01 中国人民解放军军事科学院军事医学研究院 一种小肽及其在抑制阿片成瘾性和耐受性上的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
ATE309352T1 (de) 1998-05-06 2005-11-15 Vlaams Interuniv Inst Biotech Inhibitoren der nf-kb aktivierung

Also Published As

Publication number Publication date
WO1999057133A3 (en) 2000-02-24
DE69928244T2 (de) 2006-08-10
AU4124499A (en) 1999-11-23
EP1075519A2 (de) 2001-02-14
JP2002513552A (ja) 2002-05-14
CA2328483A1 (en) 1999-11-11
US20040092430A1 (en) 2004-05-13
EP1075519B1 (de) 2005-11-09
DE69928244D1 (de) 2005-12-15
US6673897B1 (en) 2004-01-06
WO1999057133A2 (en) 1999-11-11
US7414026B2 (en) 2008-08-19
AU754434B2 (en) 2002-11-14
ES2251831T3 (es) 2006-05-01

Similar Documents

Publication Publication Date Title
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE300597T1 (de) Behandlung von geweben
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
ATE298241T1 (de) Behandlung von atemstillstand im schlaf
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE69912609D1 (de) Behandlung von in der luft enthaltenen mikroorganismen
ES2191830T3 (es) Inhibidores de trombina.
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
NO965563D0 (no) Behandling og profylakse av osteoporese
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69826282D1 (de) Handgelenkband zur vermeidung und behandlung des karpaltunnelsyndroms
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
ES2186807T3 (es) Inhibidores de trombina.
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
TR200002939T2 (tr) Paroksetin maleat
NO20010390L (no) Behandling av angstsykdommer
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
NO961113D0 (no) Behandling og forebyggelse av prostatakreft

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1075519

Country of ref document: EP

REN Ceased due to non-payment of the annual fee